S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.56 (+0.08%)
AAPL   172.85 (+0.96%)
MSFT   318.78 (+0.96%)
META   303.56 (+1.12%)
GOOGL   133.19 (+1.78%)
AMZN   128.86 (+1.37%)
TSLA   248.51 (-0.68%)
NVDA   443.66 (+1.99%)
NIO   8.71 (-3.65%)
BABA   86.15 (-0.68%)
AMD   101.94 (-0.86%)
T   14.68 (-2.26%)
F   12.23 (-1.53%)
MU   67.18 (-1.25%)
CGC   0.73 (-6.43%)
GE   108.58 (-1.78%)
DIS   81.40 (+0.43%)
AMC   8.12 (+1.63%)
PFE   33.75 (+1.75%)
PYPL   58.39 (-0.12%)
NFLX   379.16 (+0.41%)
S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.56 (+0.08%)
AAPL   172.85 (+0.96%)
MSFT   318.78 (+0.96%)
META   303.56 (+1.12%)
GOOGL   133.19 (+1.78%)
AMZN   128.86 (+1.37%)
TSLA   248.51 (-0.68%)
NVDA   443.66 (+1.99%)
NIO   8.71 (-3.65%)
BABA   86.15 (-0.68%)
AMD   101.94 (-0.86%)
T   14.68 (-2.26%)
F   12.23 (-1.53%)
MU   67.18 (-1.25%)
CGC   0.73 (-6.43%)
GE   108.58 (-1.78%)
DIS   81.40 (+0.43%)
AMC   8.12 (+1.63%)
PFE   33.75 (+1.75%)
PYPL   58.39 (-0.12%)
NFLX   379.16 (+0.41%)
S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.56 (+0.08%)
AAPL   172.85 (+0.96%)
MSFT   318.78 (+0.96%)
META   303.56 (+1.12%)
GOOGL   133.19 (+1.78%)
AMZN   128.86 (+1.37%)
TSLA   248.51 (-0.68%)
NVDA   443.66 (+1.99%)
NIO   8.71 (-3.65%)
BABA   86.15 (-0.68%)
AMD   101.94 (-0.86%)
T   14.68 (-2.26%)
F   12.23 (-1.53%)
MU   67.18 (-1.25%)
CGC   0.73 (-6.43%)
GE   108.58 (-1.78%)
DIS   81.40 (+0.43%)
AMC   8.12 (+1.63%)
PFE   33.75 (+1.75%)
PYPL   58.39 (-0.12%)
NFLX   379.16 (+0.41%)
S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.56 (+0.08%)
AAPL   172.85 (+0.96%)
MSFT   318.78 (+0.96%)
META   303.56 (+1.12%)
GOOGL   133.19 (+1.78%)
AMZN   128.86 (+1.37%)
TSLA   248.51 (-0.68%)
NVDA   443.66 (+1.99%)
NIO   8.71 (-3.65%)
BABA   86.15 (-0.68%)
AMD   101.94 (-0.86%)
T   14.68 (-2.26%)
F   12.23 (-1.53%)
MU   67.18 (-1.25%)
CGC   0.73 (-6.43%)
GE   108.58 (-1.78%)
DIS   81.40 (+0.43%)
AMC   8.12 (+1.63%)
PFE   33.75 (+1.75%)
PYPL   58.39 (-0.12%)
NFLX   379.16 (+0.41%)
NASDAQ:LUNG

Pulmonx (LUNG) Stock Forecast, Price & News

$10.04
-0.29 (-2.81%)
(As of 02:44 PM ET)
Compare
Today's Range
$10.00
$10.34
50-Day Range
$9.88
$14.00
52-Week Range
$4.07
$18.18
Volume
73,680 shs
Average Volume
342,737 shs
Market Capitalization
$381.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Pulmonx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
48.5% Upside
$15.00 Price Target
Short Interest
Healthy
3.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of Pulmonx in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$388,865 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.69) to ($1.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

515th out of 969 stocks

Surgical & Medical Instruments Industry

59th out of 100 stocks


LUNG stock logo

About Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.

LUNG Price History

LUNG Stock News Headlines

Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Iowa Gov. Kim Reynolds says her husband has lung cancer
Analysts’ Top Healthcare Picks: Pulmonx (LUNG), Omnicell (OMCL)
Pulmonx (LUNG) Receives a Sell from Bank of America Securities
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Pulmonx Reports Second Quarter 2023 Financial Results
7 Analysts Have This to Say About Pulmonx
A Preview Of Pulmonx's Earnings
See More Headlines
Receive LUNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

LUNG Company Calendar

Last Earnings
8/02/2023
Today
10/02/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LUNG
Fax
N/A
Employees
269
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+49.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-58,920,000.00
Pretax Margin
-98.92%

Debt

Sales & Book Value

Annual Sales
$53.66 million
Book Value
$4.12 per share

Miscellaneous

Free Float
35,860,000
Market Cap
$381.82 million
Optionable
Not Optionable
Beta
0.44
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Glendon E. FrenchMr. Glendon E. French (Age 61)
    CEO, Pres & Director
    Comp: $892.29k
  • Mr. David A. LehmanMr. David A. Lehman (Age 62)
    Gen. Counsel & Sec.
    Comp: $571.59k
  • Mr. Geoffrey Beran RoseMr. Geoffrey Beran Rose (Age 49)
    Chief Commercial Officer
    Comp: $560.28k
  • Dr. Derrick Sung Ph.D. (Age 50)
    Chief Financial Officer
  • Mr. Sri Radhakrishnan
    Chief Technical Officer
  • Ms. Marcee M. Maroney (Age 53)
    VP of Marketing
  • Sarah Huber
    VP of Sales (U.S.)
  • Ms. Lisa Paul (Age 59)
    Chief People Officer
  • Mr. Jérôme Erath
    Sr. VP & GM of Europe Middle-East & Africa
  • Mr. John B. McKune (Age 47)
    VP & Controller













LUNG Stock - Frequently Asked Questions

Should I buy or sell Pulmonx stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LUNG shares.
View LUNG analyst ratings
or view top-rated stocks.

What is Pulmonx's stock price forecast for 2023?

7 equities research analysts have issued 1 year target prices for Pulmonx's shares. Their LUNG share price forecasts range from $8.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 49.4% from the stock's current price.
View analysts price targets for LUNG
or view top-rated stocks among Wall Street analysts.

How have LUNG shares performed in 2023?

Pulmonx's stock was trading at $8.43 at the start of the year. Since then, LUNG shares have increased by 19.1% and is now trading at $10.04.
View the best growth stocks for 2023 here
.

When is Pulmonx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our LUNG earnings forecast
.

How were Pulmonx's earnings last quarter?

Pulmonx Co. (NASDAQ:LUNG) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $15.86 million. Pulmonx had a negative trailing twelve-month return on equity of 40.65% and a negative net margin of 99.76%. Pulmonx's revenue for the quarter was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.40) EPS.

What guidance has Pulmonx issued on next quarter's earnings?

Pulmonx updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $64.00 million-$66.00 million, compared to the consensus revenue estimate of $64.81 million.

When did Pulmonx IPO?

(LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Pulmonx's stock symbol?

Pulmonx trades on the NASDAQ under the ticker symbol "LUNG."

How do I buy shares of Pulmonx?

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulmonx's stock price today?

One share of LUNG stock can currently be purchased for approximately $10.04.

How much money does Pulmonx make?

Pulmonx (NASDAQ:LUNG) has a market capitalization of $381.82 million and generates $53.66 million in revenue each year. The company earns $-58,920,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.

How many employees does Pulmonx have?

The company employs 269 workers across the globe.

How can I contact Pulmonx?

The official website for the company is pulmonx.com. The company can be reached via phone at 1-650-364-0400 or via email at investors@pulmonx.com.

This page (NASDAQ:LUNG) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -